Table 2 Laboratory findings on admission and presence of the comorbidities in study population, overall and by survivor status
Characteristics | Total median (IQR) | Non-survivors median (IQR) | Survivors median (IQR) | P-value |
|---|---|---|---|---|
WBC count, × 109 per L, | 5.6 (4.4–7.7) | 8.3 (5.4–12.0) | 5.5 (4.3–7.2) | <0.001 |
Lymphocyte count, × 109/L | 2.3 (1.4–3.3) | 1.1 (0.6–1.7) | 2.5 (1.7–3.5) | <0.001 |
Neutrophils, × 109/Ml | 7.0 (6.1–7.9) | 8.0 (7.1–8.7) | 6.9 (6.0–7.7) | <0.001 |
Albumin, g/L | 20.6 (13.0–27.0) | 12.0 (6.0–19.0) | 21.0 (15.0–28.0) | <0.001 |
AST, U/L | 37.0 (29.0–49.0) | 45.5–35.3–62.0) | 36.0 (28.0–47.0) | <0.001 |
ALT, U/L | 31.0 (23.0–42.0) | 35.0–25.0–53.0) | 31.0 (22.0–41.0) | 0.281 |
Creatinine, mg/dl | 1.02 (0.9–1.2) | 1.20 (1.00–1.74) | 1.00 (0.90–1.20) | <0.001 |
LDH, U/L | 459 (366–576) | 578 (423–738) | 442 (363–559) | 0.006 |
Hb, g/dL | 13.9 (12.5–15.0) | 13.3 (11.5–14.9) | 13.9 (12.6–15.0) | 0.146 |
Esr, mm/h | 45.0 (27.0–65.0) | 53.0 (31.3–77.3) | 44.0 (27.0–65.0) | 0185 |
CRP, mg/l | 18 (2–64) | 45 (3–106) | 16 (2–56) | 0.008 |
Comorbidities | ||||
DM (all) | 9.0% (267) | 15.9 (48) | 8.2% (219) | < 0.001 |
Only DM | 4.7% (138) | 7.6% (23) | 4.3% (115) | 0.010 |
CVD (all) | 10.6% (314) | 17.9% (54) | 9.8% (260) | < 0.001 |
Only CVD | 5.7% (168) | 9.0% (27) | 5.3% (141) | 0.009 |
DM or CVD | 16.5% (487) | 28.9% (87) | 15.1% (400) | < 0.001 |
Any comorbidity | 25.3% (749) | 44.5% (134) | 23.2% (615) | < 0.001 |